Terms: = Kidney tumors AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Clinical Outcome
5 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma.
Wu S; Li X
Bioengineered; 2021 Dec; 12(1):1642-1662. PubMed ID: 33955826
[TBL] [Abstract] [Full Text] [Related]
3. Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer.
Pflueger D; Mittmann C; Dehler S; Rubin MA; Moch H; Schraml P
BMC Genomics; 2015 Mar; 16(1):247. PubMed ID: 25888189
[TBL] [Abstract] [Full Text] [Related]
4. Bosniak classification system: inter-observer and intra-observer agreement among experienced uroradiologists.
Graumann O; Osther SS; Karstoft J; Hørlyck A; Osther PJ
Acta Radiol; 2015 Mar; 56(3):374-83. PubMed ID: 24682404
[TBL] [Abstract] [Full Text] [Related]
5. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract] [Full Text] [Related]
